Durham Benjamin H
Department of Pediatrics, Division of Hematology-Oncology, Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA; Department of Pathology and Laboratory Medicine, Division of Hematopathology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA; Department of Oncological Pathology, Rutgers Cancer Institute, New Brunswick, NJ 08903, USA.
Hematol Oncol Clin North Am. 2025 Jun;39(3):471-490. doi: 10.1016/j.hoc.2025.03.001. Epub 2025 Apr 11.
The histiocytic and dendritic cell neoplasms encompass a clinically heterogeneous group of disorders leading to tissue damage secondary to the accumulation and infiltration of pathologic cells thought to be derived from the dendritic or monocytic lineages with accompanying inflammation. The pathophysiology of these disorders is poorly understood. Studies over the past 15 y have identified a high-frequency of BRAF, MAP2K1, and other kinase alterations in the histiocytic neoplasms. This review highlights the onslaught of molecular advancements and discusses the impact these insights have had on our understanding of the molecular pathophysiology and therapeutic targets of these rare, enigmatic diseases.
组织细胞和树突状细胞肿瘤包括一组临床异质性疾病，这些疾病会导致病理细胞（被认为源自树突状或单核细胞谱系）的积累和浸润，并伴有炎症，进而引发组织损伤。这些疾病的病理生理学尚不清楚。过去15年的研究发现，组织细胞肿瘤中BRAF、MAP2K1和其他激酶改变的频率很高。本综述重点介绍了分子进展，并讨论了这些见解对我们理解这些罕见、神秘疾病分子病理生理学和治疗靶点的影响。
